- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| Mo | Revelation Biosciences, Inc.: Revelation Biosciences Expands Acute Kidney Injury Advisory Board | 137 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / June 1, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 11.05. | Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders | 548 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / May 11, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 08.05. | Revelation Biosciences GAAP EPS of -$2.71 | 2 | Seeking Alpha | ||
| 07.05. | Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026 | 327 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / May 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 07.05. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | REVELATION BIOSCIENCES, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| REVELATION BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 15.04. | REVELATION BIOSCIENCES, INC. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 06.04. | Revelation Biosciences forms advisory board for AKI trial | 3 | Investing.com | ||
| 06.04. | Revelation Biosciences, Inc.: Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board | 342 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / April 6, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company developing innovative solutions to... ► Artikel lesen | |
| 30.03. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study | 251 | ACCESS Newswire | - A majority of CKD patients present with cellular inflammation and immunoparalysis predose --Gemini durably normalizes cellular inflammation and restores immunocompetence - SAN DIEGO, CA / ACCESS Newswire... ► Artikel lesen | |
| 24.03. | Revelation Biosciences, Inc.: REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 197 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 19.03. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.03. | Revelation Biosciences, Inc.: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference | 356 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / March 19, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 27.02. | Revelation Biosciences reports FY results | 2 | Seeking Alpha | ||
| 26.02. | Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025 | 394 | ACCESS Newswire | SAN DIEGO, CA / ACCESS Newswire / February 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflammation... ► Artikel lesen | |
| 29.01. | REVELATION BIOSCIENCES, INC. - 8-K, Current Report | - | SEC Filings | ||
| 26.01. | Revelation Biosciences kündigt Reverse-Split im Verhältnis 1:4 an | 3 | Investing.com Deutsch | ||
| 26.01. | Revelation Biosciences to implement 1-for-4 reverse stock split | 3 | Investing.com | ||
| 26.01. | Revelation Biosciences, Inc.: Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 | 731 | ACCESS Newswire | SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 26, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), announced today that, on January 28, 2026, the Company will implement... ► Artikel lesen |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 14,860 | 0,00 % | Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments | ||
| RELAY THERAPEUTICS | 15,690 | -0,06 % | Relay Therapeutics Shares Jump 18% | ||
| FULCRUM THERAPEUTICS | 3,140 | 0,00 % | Fulcrum Therapeutics, Inc.: Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review | ? Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik- (tazemetostat) and the product's subsequent global withdrawal on the benefit-risk... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,615 | +0,14 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| BEAM THERAPEUTICS | 28,970 | +0,03 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| QIAGEN | 30,890 | +0,60 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| MAZE THERAPEUTICS | 24,290 | 0,00 % | Maze Therapeutics, Inc.: Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights | Positive topline data from Phase 2 HORIZON trial of MZE829 in patients with broad AMKD provide proof-of-concept and support advancement into pivotal trial; additional HORIZON data expected in late... ► Artikel lesen | |
| HUMACYTE | 1,400 | +0,72 % | Benchmark raises Humacyte stock price target on dialysis launch hopes | ||
| EVOTEC | 5,130 | +0,69 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| ODYSSEY THERAPEUTICS | 16,930 | 0,00 % | Oppenheimer initiates Odyssey Therapeutics stock with outperform rating | ||
| PALISADE BIO | 1,850 | -0,54 % | Palisade Bio, Inc.: Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108 | Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026 Strong balance... ► Artikel lesen | |
| BIOVENTUS | 8,110 | 0,00 % | Transcript: Bioventus Q1 2026 Earnings Conference Call | ||
| ARCUS BIOSCIENCES | 24,460 | 0,00 % | Arcus Biosciences And Gilead Discontinue Phase 3 STAR-221 Study In Cancer Due To Futility | FOSTER CITY (dpa-AFX) - Biopharmaceutical company Arcus Biosciences, Inc. (RCUS) announced Friday the discontinuation of the Phase 3 STAR-221 study, being conducted in partnership with Gilead... ► Artikel lesen | |
| ALLOGENE THERAPEUTICS | 2,050 | 0,00 % | Allogene Therapeutics, Inc.: Allogene Therapeutics Announces Planned CEO Succession | David Chang, M.D., Ph.D., to Transition from President and Chief Executive Officer Following Eight Years of Outstanding Leadership and Continue to Serve on the Board of DirectorsZachary Roberts, M.D.... ► Artikel lesen | |
| IMMUNEERING | 4,280 | 0,00 % | Immuneering Corporation: Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO | - 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treatment-related... ► Artikel lesen |
Das Unternehmen REVELATION BIOSCIENCES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 1,055 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVELATION BIOSCIENCES INC finden Sie auf Wallstreet Online.